Back to top
more

Syndax Pharmaceuticals (SNDX)

(Delayed Data from NSDQ)

$12.89 USD

12.89
5,856,192

+0.32 (2.55%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $12.90 +0.01 (0.08%) 4:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

    Zacks Equity Research

    Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

      Zacks Equity Research

      Syndax Pharmaceuticals (SNDX) Reports Q2 Loss

      by Zacks Equity Research

      Syndax (SNDX) delivered earnings and revenue surprises of 18.68% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Zacks Equity Research

        Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares

        by Zacks Equity Research

        Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares

          Tirthankar Chakraborty headshot

          4 of the Best Stocks to Buy on Earnings Acceleration

          by Tirthankar Chakraborty

          Studies have shown that majority of successful stocks see acceleration in earnings before a positive stock price movement

            Zacks Equity Research

            Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?

            by Zacks Equity Research

            Syndax Pharmaceuticals (SNDX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.

              Zacks Equity Research

              Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

              by Zacks Equity Research

              Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                Zacks Equity Research

                Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

                by Zacks Equity Research

                With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                  Zacks Equity Research

                  Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?

                  by Zacks Equity Research

                  Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.

                    Zacks Equity Research

                    Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?

                    by Zacks Equity Research

                    ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.

                      Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

                        Zacks Equity Research

                        Why These 4 Biotech Stocks May Not Lose Momentum Soon

                        by Zacks Equity Research

                        The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.

                          Zacks Equity Research

                          Why Earnings Season Could Be Great for Syndax Pharmaceuticals (SNDX)

                          by Zacks Equity Research

                          Syndax Pharmaceuticals (SNDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                            Zacks Equity Research

                            Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

                            by Zacks Equity Research

                            Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.

                              Zacks Equity Research

                              Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?

                              by Zacks Equity Research

                              Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.

                                Zacks Equity Research

                                What's in Store for Puma (PBYI) this Earnings Season?

                                by Zacks Equity Research

                                Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.

                                  Zacks Equity Research

                                  What's in Store for Arena (ARNA) this Earnings Season?

                                  by Zacks Equity Research

                                  Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.

                                    Zacks Equity Research

                                    Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?

                                    by Zacks Equity Research

                                    ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.

                                      Zacks Equity Research

                                      Repros (RPRX) Q2 Earnings: What's in Store for the Stock?

                                      by Zacks Equity Research

                                      Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.

                                        Zacks Equity Research

                                        Can Ligand (LGND) Pull a Surprise This Earnings Season?

                                        by Zacks Equity Research

                                        Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.

                                          Zacks Equity Research

                                          GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?

                                          by Zacks Equity Research

                                          Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.

                                            Zacks Equity Research

                                            Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?

                                            by Zacks Equity Research

                                            Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.

                                              Zacks Equity Research

                                              What's in the Cards for Adverum (ADVM) this Earnings Season?

                                              by Zacks Equity Research

                                              Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                                                Zacks Equity Research

                                                What's in the Cards for Merrimack (MACK) in Q1 Earnings?

                                                by Zacks Equity Research

                                                Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations

                                                  Zacks Equity Research

                                                  Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.